M&T Bank’s Tarsus Pharmaceuticals TARS Stock Holding History

M&T Bank’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,035	Closed	-$213K	–	1837
2026 Q1	$213K	Sell	3,035 -80	-3%	-$5.59K	﹤0.01%	1544
2025 Q4	$255K	Sell	3,115 -580	-16%	-$43.3K	﹤0.01%	1475
2025 Q3	$219K	Buy	+3,695	New	+$182K	﹤0.01%	1348

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

M&T Bank's TARS Position: Q2 2026 in Review

M&T Bank sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 3,035 shares — an estimated $213K sold.

M&T Bank first reported a position in TARS in Q3 2025 and held it in 3 quarters. The position peaked at $255K in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

M&T Bank reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
M&T Bank sold 3,035 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $213K.
M&T Bank first reported a position in Tarsus Pharmaceuticals in Q3 2025 and held it in 3 quarters.
M&T Bank's Tarsus Pharmaceuticals position peaked at $255K in Q4 2025.
256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.